NO961086L - New proteins / polypeptides and cotransfection plasmids and living recombinant carriers for these - Google Patents

New proteins / polypeptides and cotransfection plasmids and living recombinant carriers for these

Info

Publication number
NO961086L
NO961086L NO961086A NO961086A NO961086L NO 961086 L NO961086 L NO 961086L NO 961086 A NO961086 A NO 961086A NO 961086 A NO961086 A NO 961086A NO 961086 L NO961086 L NO 961086L
Authority
NO
Norway
Prior art keywords
proteins
protein
antigenically active
active proteins
coronavirus
Prior art date
Application number
NO961086A
Other languages
Norwegian (no)
Other versions
NO961086D0 (en
Inventor
Michel Bublot
Catherine De Wannemaeker
Didier Colau
Philippe Roux-Salembien
Original Assignee
Solvay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay filed Critical Solvay
Publication of NO961086D0 publication Critical patent/NO961086D0/en
Publication of NO961086L publication Critical patent/NO961086L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Det beskrives antigent aktive proteiner som er egnet for formulering i coronavirus-vaksiner. De antigent aktive proteinene er coronavirus-proteiner betegnet S-proteinet og SM-proteinet. S-proteinet har fått enten de Al-, A2- og/eller D-antigene regioner modifisert, deletert eller utelatt på annen måte, slik at utlesning av ADE unngås, s-proteinets signalpeptid kan også være modifisert eller deletert. Det beskrives dessuten fremgangsmåter for fremstilling av de DNA- kodende sekvenser som koder for disse antigent aktive proteiner, samt for formulering av proteinene eller de DNA- kodende sekvenser som koder for disse, i farmasøytisk akseptable bærere, inklusivt levende rekombinante bærere, for å beskytte pattedyr mot coronavirusinfeksjon. De her beskrevne antigent aktive proteiner og vaksiner er særlig rettet mot FIP og beskyttelse av kattedyr mot FIPV-infeksjon.Antigenically active proteins are described which are suitable for formulation in coronavirus vaccines. The antigenically active proteins are coronavirus proteins termed the S protein and the SM protein. The S protein has either the Al, A2, and / or D antigenic regions modified, deleted, or otherwise omitted, so that ADE readout is avoided, the S protein signal peptide may also be modified or deleted. Also described are methods for preparing the DNA coding sequences encoding these antigenically active proteins, and for formulating the proteins or the DNA coding sequences encoding them, in pharmaceutically acceptable carriers, including live recombinant carriers, to protect mammals. against coronavirus infection. The antigenically active proteins and vaccines described herein are particularly targeted at FIP and protection of cats against FIPV infection.

NO961086A 1993-09-16 1996-03-15 New proteins / polypeptides and cotransfection plasmids and living recombinant carriers for these NO961086L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9319212A GB2282601B (en) 1993-09-16 1993-09-16 Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same
PCT/EP1994/002990 WO1995007987A2 (en) 1993-09-16 1994-09-07 Novel proteins/polypeptides and cotransfection plasmids and live recombinant carriers therefor

Publications (2)

Publication Number Publication Date
NO961086D0 NO961086D0 (en) 1996-03-15
NO961086L true NO961086L (en) 1996-05-09

Family

ID=10742112

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961086A NO961086L (en) 1993-09-16 1996-03-15 New proteins / polypeptides and cotransfection plasmids and living recombinant carriers for these

Country Status (10)

Country Link
EP (1) EP0720654A1 (en)
JP (1) JPH09509562A (en)
KR (1) KR960705047A (en)
AU (1) AU7615894A (en)
BR (1) BR9407507A (en)
CA (1) CA2171869A1 (en)
GB (2) GB2316681B (en)
NO (1) NO961086L (en)
WO (1) WO1995007987A2 (en)
ZA (1) ZA946887B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724385B1 (en) * 1994-08-29 1996-12-13 Rhone Merieux FELINE INFECTIOUS PERITONITIS VACCINE.
FR2741806B1 (en) * 1995-11-30 1998-02-20 Rhone Merieux RECOMBINANT LIVING VACCINE BASED ON TYPE 1 FELINE HERPESVIRUS, PARTICULARLY AGAINST FELIN INFECTIOUS PERITONITIS
WO1998001570A2 (en) * 1996-07-05 1998-01-15 Vanderbilt University Mutated antibody-dependent infection enhancing domains of hiv
FR2751223B1 (en) * 1996-07-19 1998-12-04 Rhone Merieux FELIN POLYNUCLEOTIDE VACCINE FORMULA
CN1223605C (en) * 2003-05-16 2005-10-19 中国科学院微生物研究所 Polypeptide medicine for inhibiting SARS coronavirus, and derivatives and use thereof
CN113321714B (en) * 2020-02-28 2022-12-09 深圳市亚辉龙生物科技股份有限公司 Recombinant N protein of SARS-CoV-2 and its preparation and purification method
US20230331782A1 (en) * 2020-09-08 2023-10-19 The Trustees Of The University Of Pennsylvania Compositions and Methods for Reducing Risk of Vaccine-Enhanced Disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL76751A (en) * 1984-11-01 1991-04-15 American Home Prod Method and oral vaccines against infectious organisms using live,recombinant adenovirus for the production of antibodies
EP0264979A1 (en) * 1986-09-05 1988-04-27 Duphar International Research B.V New antigenically active proteins and peptides, and feline infectious peritonitis virus (FIPV) vaccines
CA2005291C (en) * 1988-12-30 1999-01-26 Beverly Dale Feline infectious peritonitis virus diagnostic tools
CA2020740A1 (en) * 1989-07-12 1991-01-13 Harry Vennema Antigenically active proteins/peptides, and feline infectious peritonitis virus (fipv)-vaccines
NZ240558A (en) * 1990-11-14 1994-11-25 Smithkline Beecham Corp Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease
JPH07504897A (en) * 1992-02-18 1995-06-01 パーヘリオン　コーポレーション Feline infectious peritonitis vaccine and preparation method
JPH07508176A (en) * 1992-05-08 1995-09-14 ファイザー・インコーポレイテッド universal coronavirus vaccine
CA2135200C (en) * 1992-05-08 2001-03-27 Timothy J. Miller Canine coronavirus s gene and uses therefor

Also Published As

Publication number Publication date
GB2282601A (en) 1995-04-12
GB2282601B (en) 1998-04-15
EP0720654A1 (en) 1996-07-10
GB2316681B (en) 1998-04-15
GB2316681A (en) 1998-03-04
GB9319212D0 (en) 1993-11-03
NO961086D0 (en) 1996-03-15
WO1995007987A2 (en) 1995-03-23
WO1995007987A3 (en) 1995-06-22
KR960705047A (en) 1996-10-09
AU7615894A (en) 1995-04-03
GB9722558D0 (en) 1997-12-24
JPH09509562A (en) 1997-09-30
ZA946887B (en) 1995-06-27
BR9407507A (en) 1997-01-07
CA2171869A1 (en) 1995-03-23

Similar Documents

Publication Publication Date Title
HUP9901186A2 (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
NZ505322A (en) Protein expression in baculovirus vector expression systems using low multiplicity of infection
NO177678C (en) Method for Preparing a Therapeutically Active, Recombinant Protein having ASP Activity, Expression System, and DNA Encoding the Protein
GB9224584D0 (en) Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
CA2224257A1 (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
NZ521270A (en) Altered strain of the Modified Vaccinia virus Ankara (MVA) for growth in a continuous vero cell line
HUP0104609A2 (en) Plasmid maintenance system for antigen delivery
MXPA01008966A (en) Nucleic acid respiratory syncytial virus vaccines.
RU2001107969A (en) IMMUNODOMINANT ANTIGENIC PROTEIN MASS OF 120 KDA AND THE EHRLICHIA CANIS GENE
DE69737413D1 (en) Bakterioferritin aus helicobacter pylori
NO961086L (en) New proteins / polypeptides and cotransfection plasmids and living recombinant carriers for these
DE68926679D1 (en) PHYSIOLOGICALLY ACTIVE POLYPEPTIDE, RECOMBINANT PLASMIDE, RECOMBINANT MICROBIAL CELLS, MEDICAL PREPARATION AND METHOD FOR OBTAINING THE PURIFIED POLYPEPTIDE
AU4826493A (en) Anti-feline immunodeficiency virus (fiv) vaccines
ATE103297T1 (en) PEPTIDE, IMMUNOGENIC COMPOSITION AND VACCINE OR MEDICINAL PREPARATION, A METHOD OF IMMUNIZING A MAMMAL AGAINST LHRH AND METHOD OF IMPROVING MEA.
HUP9901035A2 (en) Parapoxviruses containing foreign dna, their production and their use in vaccines
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
AU4149699A (en) Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses
DK457687D0 (en) ANTIGENIC ACTIVE PROTEINS AND PEPTIDES AND VACCINES AGAINST VIRUS FOR FELIN PERITONITIS (FIPV) CONTAINING SUCH PROTEIN OR PEPTIDES
IL75553A0 (en) Ache like peptide
NO177859C (en) Method of producing angiogenic factor
WO2021207848A1 (en) Mers-cov vaccine
RU94045154A (en) Polypeptides, their fragments and variants, preparation, dna, vector, cell, method of polypeptide producing, vaccines, protection method, antibody and its fragment, their use, dna use, method of antigen identification
RU93031157A (en) METHOD OF INCREASING THE PRODUCTIVITY OF AGRICULTURAL ANIMALS WITH THE HELP OF CHEMICAL PROTEIN CONTAINING SOMATOSTATIN, IMMUNOGENIC COMPOSITION, FACTORS OF IMPROVING PRODUCTIVITY
DK204588A (en) HUMAN RHINOVIRUS PEPTIDES, PROCEDURES FOR THEIR PREPARATION AND VACCINES CONTAINING SUCH PEPTIDES
ES2012815A6 (en) Vaccine against melanoma